Clinical Trial Update: OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients [Phase 1]

View source ↗

Summary

Phase 1 PK study of OXN PR Tablet 5/2.5 mg and 20/10 mg in Chinese patients with moderate to severe chronic non-malignant chronic pain completed; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• OXN PR Tablet 20/10 mg
• OXN PR Tablet 5/2.5 mg

Snippet

Sponsor: Mundipharma (China) Pharmaceutical Co. Ltd | Conditions: Chronic Pain | Phase 1 | Status: COMPLETED | Results posted: 2019-07-17